Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: Multi-Center placebo-controlled Double-Blind Randomized Trial

Next Previous
X
Search
Trial Profile

Effect of Empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: Multi-Center placebo-controlled Double-Blind Randomized Trial

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Empagliflozin (Primary)
  • Indications Cardiovascular disorders
  • Focus Therapeutic Use
  • Acronyms EMBODY

    • Most Recent Events

    • 17 Nov 2020 Results (n=96) of subanalysis assessing the time-course of renal function on baseline, weeks 4, 12 and 24 presented at the American Heart Association Scientific Sessions 2020
    • 01 Sep 2020 Results of sub-group analysis presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology
    • 10 Dec 2019 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top